|Cohort||Population||Genomic DNA||RNA||Plasma||Serum||CSF||Whole Blood||Urine||Saliva (Passive Drool)|
|FTLD||FTLD Cases, Controls||✔||✔||✔||✔||✔|
Examination of the Earliest Symptoms and Biomarkers of FTLD
- Study Subjects
Subjects from this study are from a single family with a genetic mutation for FTLD who are approaching the age of disease onset; members of the offspring of the single family participated in this longitudinal study examining cognition, behavior, psychiatric symptoms, and lifestyle features. BioSEND has samples available from 64 subjects.
- Available Data
Demographic, lifestyle, and cognitive data are available for subjects in the FTLD study.
Please contact firstname.lastname@example.org for more information on available data.
- Available Biospecimens
DNA and RNA from blood, CSF, whole blood, and plasma are available.
Please contact email@example.com for information about available biosamples.
The FTLD Study, Examination of the Earliest Symptoms and Biomarkers of FTLD MAPT Carriers (R01NS076837) aimed to better understand and characterize early-stage FTLD, with the larger goal of facilitating earlier disease detection and preventing irreversible neurological changes. Investigators who request access to this resource will be required to comply with the BioSEND Biospecimens User Agreement and/or the Data Use Agreement and to adhere to the Publication Policy.